Akari Therapeutics entered into an amendment to its May 2026 securities purchase agreement. The amendment consolidates the previously scheduled second (June 15) and third (July 15) tranches of a private placement into a single combined closing. The combined closing occurred on June 26, 2026, resulting in the issuance of 980,395 ADSs or prefunded warrants. Delivery of Series H, I, and J warrants remains contingent upon shareholder approval at the annual general meeting on June 30, 2026.